Xalud Therapeutics Inc. raised an oversubscribed $30 million series C financing to continue advancing its lead candidate, XT-150, for regulating interleukin-10 in order to treat pathologic inflammation. The injectable, plasmid DNA gene therapy expresses IL-10v, a modified version of the cytokine IL-10, and is in a phase IIb study for treating moderate to severe pain caused by osteoarthritis (OA) of the knee.
Pharmacyte Biotech Inc. has raised $90 million to move its live cell encapsulation technology for cancer and diabetes further into the clinic. CEO Kenneth Waggoner told BioWorld that the first task is to work through studies and gather other information required by the FDA to get a clinical hold, imposed last November, lifted on trials in pancreatic cancer.
Vigencell Inc., a company focused on immune cell therapy, raised ₩99.4 (US$85.17 million) through an IPO on South Korea’s Kosdaq board and plans to use the funds to drive its R&D and company operations. “We particularly want to increase the competitiveness of our pipeline by advancing our technology and clinical development,” Vigencell CEO Tai-Gyu Kim told BioWorld. “We will also expand our discovery of new candidates and R&D in general, as well as updating our facilities and hiring researchers.”
DUBLIN – Cardior Pharmaceuticals GmbH has closed a €64 million (US$75 million) series B round, enabling it to move its lead micro-RNA (miRNA) inhibitor program into late-stage development in heart failure. The financing sets the stage for a potential revival of a therapeutic modality that had otherwise fallen out of favor with investors and with big pharma.
Atavistik Bio Inc. has raised $60 million in a series A financing round to advance its preclinical molecules targeting genetically validated targets in metabolic diseases and cancer.
RSS
